NEW YORK (GenomeWeb) – Veracyte reported after the close of the market on Monday that its third quarter 2017 revenues declined 6 percent year over year.

For the three months ended Sept. 30, the genomic testing firm reported total revenues of $17.5 million, compared to $18.6 million in Q3 2016, missing the average analyst estimate of $19.6 million.

The firm said that revenue accrued for tests performed during the quarter increased 24 percent, but was offset by the impact of higher cash collections in the prior-year quarter for tests performed prior to July 1, 2016.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jun
14
Sponsored by
Sophia Genetics

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
26
Sponsored by
Lexogen

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.